- Home
- ENTA vs TVGN Comparison
ENTA vs TVGN Comparison
Compare ENTA & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- TVGN
- Stock Information
- Founded
- ENTA 1995
- TVGN 2020
- Country
- ENTA United States
- TVGN United States
- Employees
- ENTA N/A
- TVGN N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- TVGN Blank Checks
- Sector
- ENTA Health Care
- TVGN Finance
- Exchange
- ENTA Nasdaq
- TVGN Nasdaq
- Market Cap
- ENTA 164.6M
- TVGN 179.0M
- IPO Year
- ENTA 2013
- TVGN N/A
- Fundamental
- Price
- ENTA $8.28
- TVGN $0.87
- Analyst Decision
- ENTA Strong Buy
- TVGN Strong Buy
- Analyst Count
- ENTA 4
- TVGN 1
- Target Price
- ENTA $22.25
- TVGN $10.00
- AVG Volume (30 Days)
- ENTA 158.9K
- TVGN 517.1K
- Earning Date
- ENTA 08-11-2025
- TVGN 08-14-2025
- Dividend Yield
- ENTA N/A
- TVGN N/A
- EPS Growth
- ENTA N/A
- TVGN N/A
- EPS
- ENTA N/A
- TVGN N/A
- Revenue
- ENTA $64,806,000.00
- TVGN N/A
- Revenue This Year
- ENTA N/A
- TVGN N/A
- Revenue Next Year
- ENTA $1.65
- TVGN N/A
- P/E Ratio
- ENTA N/A
- TVGN N/A
- Revenue Growth
- ENTA N/A
- TVGN N/A
- 52 Week Low
- ENTA $4.09
- TVGN $0.26
- 52 Week High
- ENTA $13.37
- TVGN $3.09
- Technical
- Relative Strength Index (RSI)
- ENTA 49.11
- TVGN 36.30
- Support Level
- ENTA $8.25
- TVGN $0.86
- Resistance Level
- ENTA $9.08
- TVGN $0.99
- Average True Range (ATR)
- ENTA 0.44
- TVGN 0.05
- MACD
- ENTA -0.08
- TVGN 0.00
- Stochastic Oscillator
- ENTA 3.78
- TVGN 9.27
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.